ArticleNature cell biology2013
Cancer stem cells: the challenges ahead.
Article in Nature cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 421 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
421 citing papers in PubMed.
- Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.Cancer chemotherapy and pharmacology · 2024Trial
- Digital Twins for Targeted Therapy in Head and Neck Cancer: From Molecular Stratification to Resistance-Aware Combination Strategies.Current oncology (Toronto, Ont.) · 2026Review
- Investigating the expression of CTLA-4 and CD28 genes as immune regulators in patients with colorectal polyps.BMC cancer · 2026Article
- Integrative single-cell and bulk transcriptomics define cell death patterns and ZDHHC22 in gastric cancer progression.BMC medical genomics · 2026Article
- Potential Role of Exosomes in the Pathogenesis, Diagnosis, and Treatment of Ovarian Cancer.Cancers · 2026Review
- Targeting the IRE1α-XBP1 signaling axis impairs tumor growth and promotes myogenic differentiation in rhabdomyosarcoma.Communications biology · 2026Article
- Targeting the IRE1α-XBP1 signaling axis impairs tumor growth and promotes myogenic differentiation in rhabdomyosarcoma.bioRxiv : the preprint server for biology · 2026Article
- One-Stone-Two-Birds Carrier-Free Nano-Cocktail Enables Synergistic Eradication of Cancer Cells/Stem Cells in Breast Cancer Treatment.Exploration (Beijing, China) · 2026Article
- A bibliometric and visual analysis of colorectal cancer-diabetes comorbidity.Discover oncology · 2026Article
- TPX2-mediated autophagy maintains cancer stemness in LUAD: bioinformatic screening and functional validation.Frontiers in oncology · 2026Article
- Comprehensive molecular characterization of high-stemness gastric cancer cells using single-cell transcriptomics, spatial mapping, and machine learning.NPJ precision oncology · 2025Article
- Characterization of stem cell landscape and identification of stemness-related gene ENY2 in colorectal cancer by intergrated transcriptomic analysis.Global medical genetics · 2025Article
- Biology of stem cell paradox: a double-edged sword-implications for cancer therapy.Cancer cell international · 2025Review
- Cancer stem cells: landscape, challenges and emerging therapeutic innovations.Signal transduction and targeted therapy · 2025Review
- Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities.Cancers · 2025Review
- The invadosome of stem-like cancer cells: metastasis machinery and targetable vulnerability.Cancer metastasis reviews · 2025Review
- New oligomycin derivatives inhibit anchorage-independent growth of pancreatic cancer cells.The Journal of antibiotics · 2025Article
- Adhesion strength of tumor cells predicts metastatic disease in vivo.Cell reports · 2025Article
- Integrated analysis of single-cell and bulk RNA-sequencing to predict prognosis and therapeutic response for colorectal cancer.Scientific reports · 2025Article
- Serum metabolic characteristics associated with the deterioration of colorectal adenomas.Scientific reports · 2025Article
361 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) have been proposed as the driving force of tumorigenesis and the seeds of metastases. However, their existence and role remain a topic of intense debate. Recently, the identification of CSCs in endogenously developing mouse tumours has provided further support for this concept. Here I discuss the challenges in identifying CSCs, their dependency on a supportive niche and their role in metastasis, and propose that stemness is a flexible — rather than fixed — quality of tumour cells that can be lost and gained.
Indexed as
Identifiers
23548926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.